

UNITED STATES PATENT AND TRADEMARK OFFICE



UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER OF PATENTS AND TRADEMARKS Washington, D.C. 20231 www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.	
09/905,657	07/13/2001	Christa Lechelt-Kunze	Mo-6431/LeA 34,730	5977	
157 7:	590 10/01/2002				
BAYER CORPORATION			EXAMINER		
PATENT DEP. 100 BAYER R	OAD		KRUSE, D	RUSE, DAVID H	
PITTSBURGH, PA 15205			ART UNIT	PAPER NUMBER	
			1638	<u> </u>	
			DATE MAILED: 10/01/2002		

Please find below and/or attached an Office communication concerning this application or proceeding.

PTO-90C (Rev. 07-01)

		Application N .	Applicant(s)		
Offic Action Summary		09/905,657	LECHELT-KUNZE ET AL.		
		Examin r	Art Unit		
	•	David H Kruse	1638		
	The MAILING DATE f this communication app	ears on the cover sheet with the o	correspondenc address		
Period fo	• •		(0)		
A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) FROM THE MAILING DATE OF THIS COMMUNICATION. - Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication. - If the period for reply specified above is less than thirty (30) days, a reply within the statutory minimum of thirty (30) days will be considered timely. - If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication. - Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). - Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).					
Status 1\⊠	Personaliza to communication(s) filed on 12 /	ulu 2004			
1)⊠ 2a)⊟	Responsive to communication(s) filed on $\underline{13 J}$. This action is FINAL . 2b) \boxtimes Thi	is action is non-final.			
· <u> </u>	,		recognition as to the morits is		
3) Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under <i>Ex parte Quayle</i> , 1935 C.D. 11, 453 O.G. 213.					
Disposition of Claims					
4) \boxtimes Claim(s) <u>15-17,20,21 and 23-46</u> is/are pending in the application.					
4a) Of the above claim(s) is/are withdrawn from consideration.					
5) Claim(s) is/are allowed.					
· <u> </u>	Claim(s) is/are rejected.				
·	Claim(s) is/are objected to.				
•	Claim(s) <u>15-17,20,21 and 23-46</u> are subject to on Papers	restriction and/or election require	ement.		
· · ·	•				
9) The specification is objected to by the Examiner. 10) The drawing(s) filed on is/are: a) □ accepted or b) □ objected to by the Examiner.					
10)					
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a). 11) The proposed drawing correction filed on is: a) approved b) disapproved by the Examiner.					
If approved, corrected drawings are required in reply to this Office action.					
12) The oath or declaration is objected to by the Examiner.					
Priority under 35 U.S.C. §§ 119 and 120					
13) Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).					
a) ☐ All b) ☐ Some * c) ☐ None of:					
1. Certified copies of the priority documents have been received.					
	2. Certified copies of the priority documents have been received in Application No				
 3. Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)). * See the attached detailed Office action for a list of the certified copies not received. 					
14) Acknowledgment is made of a claim for domestic priority under 35 U.S.C. § 119(e) (to a provisional application).					
a) ☐ The translation of the foreign language provisional application has been received. 15)☐ Acknowledgment is made of a claim for domestic priority under 35 U.S.C. §§ 120 and/or 121.					
Attachment(s)					
2) Notice	e of References Cited (PTO-892) e of Draftsperson's Patent Drawing Review (PTO-948) nation Disclosure Statement(s) (PTO-1449) Paper No(s)	5) Notice of Informal	y (PTO-413) Paper No(s) Patent Application (PTO-152)		

Art Unit: 1638

DETAILED ACTION

Election/Restrictions

- 1. Restriction to one of the following inventions is required under 35 U.S.C. § 121:
 - Claims 15, 16, 27-30 and 37-46, drawn to a method of finding a chemical compound which binds a polypeptide comprising contacting a polypeptide with a chemical compound, classified in class 435, subclass 15, for example.
 - II. Claims 17, 31 and 32, drawn to a method for finding a compound which alters the expression of polypeptides comprising contacting a host cell with a chemical compound, classified in class 435, subclass 6, for example.
 - III. Claims 20, 21, 25 and 26, drawn to an herbicidal compound, classified in class 504, subclass 116.1, for example.
 - IV. Claims 23, 33 and 34, drawn to a transgenic plant having altered intracellular concentration of a long chain fatty acid elongase, classified in class 800, subclass 281, for example.
 - V. Claim 24, drawn to a mutant plant having altered activity or expression pattern of a long chain fatty acid elongase, classified in class 800, subclass 276, for example.
 - VI. Claims 35 and 36, drawn to a method of determining a target compound that binds to a nucleic acid, classified in class 435, subclass 6, for example.

Art Unit: 1638

The inventions are distinct, each from the other because of the following reasons:

- 2. Inventions I and II and VI are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions are unrelated because the method of Group I has different method steps, different starting materials and different effects than that of either of Group II or VI.
- 3. Inventions I and II and Invention III are related as processes of making and product made. The inventions are distinct if either or both of the following can be shown: (1) that the process as claimed can be used to make other and materially different product or (2) that the product as claimed can be made by another and materially different process (MPEP § 806.05(f)). In the instant case the herbicidal compound of Group III can be identified by either the method of Group I or the method of Group II.
- 4. Inventions I and II and Invention IV are related as product and processes of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the transgenic plant of Group IV can be used in either of the method of Group I or the method of Group II. In addition, the product identified by the method of Group I could be distinct from the product identified by the method of Group II.

Art Unit: 1638

5. Inventions I and II and Invention V are related as product and processes of use. The inventions can be shown to be distinct if either or both of the following can be shown: (1) the process for using the product as claimed can be practiced with another materially different product or (2) the product as claimed can be used in a materially different process of using that product (MPEP § 806.05(h)). In the instant case the mutant plant of Group V can be used in either of the method of Group I or the method of Group II. In addition, the product identified by the method of Group I could be distinct from the product identified by the method of Group II.

Page 4

- 6. Inventions III and IV are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions are unrelated because the transgenic plant of Group IV is structurally, functionally and compositionally distinct from the herbicidal compound of Group III.
- 7. Inventions III and V are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions are unrelated because the mutant plant of Group V is structurally, functionally and compositionally distinct from the herbicidal compound of Group III.
- 8. Inventions III and VI are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of

Art Unit: 1638

operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions are unrelated because the herbicidal compound cannot be used in the method of Group VI.

- 9. Inventions IV and V and VI are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions are unrelated because neither the transgenic plant nor the mutant plant of either Group IV or Group V, respectively, can be used in the method of Group VI.
- 10. Inventions IV and V are unrelated. Inventions are unrelated if it can be shown that they are not disclosed as capable of use together and they have different modes of operation, different functions, or different effects (MPEP § 806.04, MPEP § 808.01). In the instant case the different inventions are unrelated because the transgenic plant of Group IV is structurally, functionally and compositionally distinct from the mutant plant of Group V.
- 11. Because these inventions are distinct for the reasons given above and have acquired a separate status in the art as shown by their different classification, recognized divergent subject matter, and because the search required for one of the groups is not required for another, restriction for examination purposes as indicated is proper.

Page 5

Application/Control Number: 09/905,657 Page 6

Art Unit: 1638

12. Applicant is advised that the reply to this requirement to be complete within one month (not less than 30 days) must include an election of the invention to be examined

even though the requirement be traversed (37 CFR § 1.143).

13. Applicant is reminded that upon the cancellation of claims to a non-elected

invention, the inventorship must be amended in compliance with 37 CFR § 1.48(b) if

one or more of the currently named inventors is no longer an inventor of at least one

claim remaining in the application. Any amendment of inventorship must be

accompanied by a request under 37 CFR § 1.48(b) and by the fee required under 37

CFR § 1.17(i).

14. Any inquiry concerning this communication or earlier communications from the

examiner should be directed to David H. Kruse, Ph.D. whose telephone number is (703)

306-4539. The examiner can normally be reached on Monday to Friday from 8:00 a.m.

to 4:30 p.m.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's

supervisor, Dr. Amy Nelson can be reached at (703) 306-3218. The fax telephone

number for this Group is (703) 872-9306 Before Final or (703) 872-9307 After Final.

Any inquiry of a general nature or relating to the status of this application or

proceeding should be directed to Kim Davis whose telephone number is (703) 305-

3015.

AMY J. NELSON, PH.D SUPERVISORY PATENT EXAMINER TECHNOLOGY CENTER 1600

David H. Kruse, Ph.D. 24 September 2002